2. HYPERTENSION
Defintion :
“An adult is considered to be
hypertensive when systemic BP>140/90
mm Hg or more on atleast two
occasions measured at least 1or2
weeks apart.”
5. Essential Hypertension
95% of all cases of hypertension
characterized by a familial incidence and
inherited biochemical abnormalities.
6. Factors causing Genesis
increased sympathetic nervous system activity in
response to stress
overproduction of sodium-retaining hormones and
vasoconstrictors
high sodium intake
inadequate dietary intake of potassium and
calcium
increased renin secretion
deficiencies of endogenous vasodilators such as
prostaglandins and nitric oxide (NO)
the presence of medical diseases such as
diabetes mellitus and obesity
7. Additional factors
Genetic factors
1.Glucocorticoid remediable HTN:
2.Syndrome of apparent
mineralocorticoid excess
Alcohol and tobacco use
Obstructive sleep apnea
Physical activity
10. 2.Secondary Hypertension
37
JNC VII Causes of Secondary HypertensionJNC VII Causes of Secondary Hypertension
Medical Conditions
Sleep apnea
Thyroid or parathyroid disease
Aortic coarctation
Pheochromocytoma
Cushing’s syndrome
Chronic steroid therapy
Renovascular disease
Primary hyperaldosteronism
Chronic kidney disease
Drugs
Alcohol
Cocaine or amphetamines
Ephedra, mu huang, bitter orange
Erythropoietin
Cyclosporine or tacrolimus
Sympathomimetics
Adrenal steroids
Oral contraceptives
NSAIDS
Chobanian AV et al. JAMA. 2003;289:2560-2572
NSAIDS=Non-steroidal anti-inflammatory drugs
11. Isolated systolic Hypertension
Aging with associated aortic rigidity
Increased cardiacoutput
a. Thyrotoxicosis
b. Anemia
c. Aortic regurgitation
Decreased peripheral vascular resistance
a. Arteriovenous shunts
b. Paget's disease
12. Treatment of Essential
Hypertension
GOALS
to decrease systemic blood pressure to lower than 140/90
mm Hg, but in the presence of diabetes mellitus or renal
disease, the goal is lower than 130/80 mm Hg
decreasing the incidence of cerebrovascular accidents
decreases the morbidity and mortality associated with
ischemic heart disease
prevents progression to a more severe stage of
hypertension and decreases the risk of congestive heart
failure and renal failure.
13. LIFE STYLE MODIFICATION-
Patients who do not manifest clinical evidence of
cardiovascular disease or target organ damage
may benefit from a trial of lifestyle modification
PHARMACOLOGICAL THERAPY
-Patients with concomitant risk factors
(hypercholesterolemia, diabetes mellitus, tobacco
abuse, family history, age older than 60 years)
and
-evidence of target organ damage are most likely
to benefit from pharmacologic antihypertensive
therapy
14.
15.
16. Treatment of Secondary
Hypertension
Surgical Therapy:
1. correction of renal artery stenosis via
angioplasty or direct repair and
2. adrenalectomy for adrenal adenoma or
pheochromocytoma
Pharmacologic Therapy:
renal artery revascularization is not possible
blood pressure control with ACE inhibitors alone
or in combination with diuretics.
Renal function and serum potassium
concentration must be carefully monitored
17. Hypertensive Crises
Definition:
Hypertensive crises typically present with a blood
pressure of higher than 180/120
categorized as
1. hypertensive urgency
2. hypertensive emergency
based on the presence or absence of impending
or progressive target organ damage
18. Hypertensive Emergency
evidence of acute or ongoing target organ damage
1. encephalopathy,
2. intracerebral hemorrhage,
3. acute left ventricular failure with pulmonary edema
4. unstable angina,
5. dissecting aortic aneurysm
6. acute myocardial infarction,
7. eclampsia,
8. microangiopathic hemolytic anemia,
9. renal insufficiency
require prompt pharmacologic intervention to
lower the systemic blood pressure
19. Treatment
goal of treatment to decrease the diastolic blood
pressure promptly but gradually
A precipitous decrease in blood pressure to
normotensive levels may provoke coronary or
cerebral ischemia
Typically, mean arterial pressure is reduced by about
20% within the first 60 minutes and then more
gradually.
Thereafter, the blood pressure can be reduced to
160/110 over the next 2 to 6 hours as tolerated by the
20. Hypertensive Urgency
Hypertensive urgencies are situations in which
BP is severely elevated, but the patient is not
exhibiting evidence of target organ damage.
These patients can present with headache,
epistaxis, or anxiety.
Selected patients may benefit from oral
antihypertensive therapy
21.
22.
23. Management of Anesthesia in
Patients with Essential Hypertension
Pre operative evaluation:
1. Determine adequacy of blood pressure control
2. Review pharmacology of drugs being
administered to control blood pressure
3. Evaluate for evidence of end-organ damage
4. Continue drugs used for control of blood
pressure
24. review the pharmacology and potential side effects of the
drugs being used for antihypertensive therapy
hemodynamic instability and hypotension will occur during
anesthesia in patients receiving ACE inhibitors
discontinue ACE inhibitors 24 to 48 hours preoperatively in
patients at high risk of intraoperative hypovolemia and
hypotension.
ARBs increases the potential for hypotension during
anesthesia.
necessitating use of vasopressin or one of its analogues
25. risk of rebound hypertension should certain drugs,
especially β-adrenergic antagonists and clonidine,
be abruptly discontinued.
Hypokalemia (<3.5 mEq/L) despite potassium
supplementation is a common preoperative finding in
patients being treated with diuretics.
Hyperkalemia can be seen patients being treated
with ACE inhibitors
26. Induction of Anesthesia
Hypotension during induction in patients continuing
ACE inhibitor or ARB therapy.
Direct laryngoscopy and tracheal intubation can
produce significant hypertension in patients with
essential hypertension
deep inhalation anesthesia or injection of an opioid,
lidocaine, β-blocker, or vasodilator protect from MI
Direct laryngoscopy that does not exceed 15
seconds in duration helps minimize blood pressure
27. Maintenance of Anesthesia
to minimize wide fluctuations in blood pressure.
Management of intraoperative blood pressure
lability is as important as preoperative control of
hypertension in these patients.
Problems
1. Intraoperative hypertension
2. Intraoperative hypotension
28. 1. Intraoperative hypertension
produced by painful stimulation, i.e., light anesthesia
A nitrous oxide–opioid technique can be used for
maintenance of anesthesia
Antihypertensive medication by bolus or by
continuous infusion is an alternative to the use of a
volatile anesthetic for blood pressure control
intraoperatively
no evidence that a specific neuromuscular blocker is
best for patients with hypertension
29. Intraoperative Hypotension
Hypotension during maintenance of anesthesia may
be treated by decreasing the depth of anesthesia
and/or by increasing fluid infusion rates.
Cardiac rhythm disturbances that result in loss of
sequential atrioventricular contraction such as
junctional rhythm and atrial fibrillation can also create
hypotension
ephedrine or phenylephrine may be necessary to
restore vital organ perfusion pressures
patients treated with ACE inhibitors or ARBs is
responsive to administration of i.v fluids or
vasopressin.
30. Postoperative Management
Postoperative hypertension is common in patients
with essential hypertension.
assessment and treatment to decrease the risk of
myocardial ischemia, cardiac dysrhythmias,
congestive heart failure, stroke, and bleeding.
conversion can be made to the patient's usual
regimen of oral antihypertensive medication
31. Chronic Renal Failure
CRF occurs where GFR has been reduced to 10%
(20ml/min) of normal function and ESRD when GFR falls
below 5% (10ml/min).
The relationship between serum creatinine and GFR is
not linear (figure 1) and serum creatinine does not rise
until GFR has fallen below 50%.
32. Stages of Chronic Kidney Disease
(NKF,2003)
Stage Description GFR
1 Kidney Damage with
normal GFR
>/=90
2 Kidney Damage with
mild fall in GFR
60-89
3 Moderate fall in GFR 30-59
4 Severe fall in GFR 15-29
5 Kidney Failure <15
34. ESRD AGE >18Yrs
Type 1 D.M.
Chr. G.N.
Type 2 D.M.
Hypertensive N.S.
MPGN
Obstructive uropathy
Ig A Nephropathy
SLE
Others 21.6
35. Pathophysiologic
consequences
Cardiovascular
Hyper tension develops in approximately 80%
patients
Sodium and water retention, hyper secretion of renin
– high conc. of renin, angiotensin-װ and
aldosterone with LVH, hypertensive
cardiomyopathy, hypertensive crises
Ischemic heart disease
36. Cardiovascular
Atherosclerosis and vascular calcification (high
calcium&phosphate product).
Uremic pericarditis if untreated leads to cardiac
tamponade & later constrictive pericarditis.
Dysrhythmias due to Hyperkalemia and
hypocalcaemia.
37. Haematological effects
Anaemia
Due to decreased erythropoietin production,
Diminished erythrocyte survival,
Diminished production of R.B.C’s due to fibrosis of
bonemarrow.
Reduced dietary intake and absorption of iron.
Fragility of capillaries
Qualitative dysfunction of platelets due to decreased
platelet factor III activity.
Aluminium toxicity & iron,folate,vitB6,B12.
38. Haematological effects
Absence of correction of the anaemia,there are
compensatory mechanisms for the reduction in
oxygen carrying capacity .
increase in cardiac output & an increase in the
2,3DPG.
Severe anaemia affects the blood-gas partition
coefficient so onset & recovery is faster .
39. Respiratory system
Pulmonary congestion & edema are seen with
resultant hypoxaemia & hypocapnia .
Intra peritoneal fluid causes diaphragmatic splinting
with basal atelectasis & shunting.
Uremia can cause pleuritis.
Immunosuppressed patients are more susceptable
to pulmonary infections .
41. Electrolyte and fluid
disturbances
Uremic patients tolerate hyperkalaemia & it is
safe to administer anaesthesia in the presence of
higher K levels,unless there are ECG changes.
Methods for preoperative correction include
glucose-insulin,sodium bicarbonate ,10ml of 10%
of calcium gluconate,hyperventilation ,furosemide
or dialysis & kayexilate .
42. Endocrine
Secondary hyperparathyroidismosteomalacia,
renal osteodystrophy (bone pain, fractures),
Insulin half life is prolonged in CRF, due to
decreased tubular metabolism of insulin.
However there is post receptor defect in insulin
action, and relative insulin resistance.
Hyperprolactinaemia – loss of libido in both sexes,
amenorrhea in women.
43.
44. Coagulation
Several abnormalities of coagulation factors like(dec plat
F III, platelet dysfn).
Pletelet FIII decreased because of accumulation of toxic
waste products,
These products are removed by dialysis.
Other methods platelet , cryoprecipitate &
desmopressin acetate .
Desmopressin acetate increase the activity of factors
VIII,XII,von willebrand factor.
45. Central nervous system
Features of uremia are initially malaise & reduced
mental ability.
Others are seizures,coma & death .
Dialysis associated with dysequilibrium syndrome.
Due to sudden changes in extracellular
volume,electrolytes & cerebral edema.
Presents as dehydration,weakness,
vomiting,hypotension ,convulsions & coma.
46. Peripheral neuropathy
Demyelination of medullated fibres, long fibres
are involved earlier.
Sensory neuropathy: paraesthesia.
Motor neuropathy: foot drop.
Uremic autonomic neuropathy: postural
hypotension, diarrhea.
47. Myopathy
A combination of poor nutrition,
hyperparathyroidism, Vit.D deficiency and
disorders of electrolyte metabolism.
Muscle cramps are common & quinine sulphate
will be helpful.
Restless leg syndrome patients legs are jumpy
during the night which is improved by
clonazepam .
48. Gastrointestinal tract
Presents with anorexia,nausea &vomiting,GI bleed &
diarrhoea .
Delayed gastric emptying,increase in acidity &
gastric volume .
Pt benefits from administration of histamine H2
receptor antagonist as a premedication .
Ascites is a rare but important complications .
49. Immune system
Uremia impairs normal immune mechanisms .
It is obtunded further by giving
immunosuppresant therapy
As a result sepsis remains a major prob.
So strict aseptic technique is followed .
50. altered drug handling in CRF
volume of distribution is usually decreased, but
may be increased if there is fluid retention
Hypoalbuminaemia and acidosis increase the
free drug availability of highly protein bound drugs
The doses of benzodiazepines and thiopentone
may need to be reduced by 30% - 50%
The elimination of highly ionised, water soluble
drugs such as atropine are partially or completely
dependent on renal excretion and may be
markedly reduced.
51. The elimination of volatile anaesthetic agents is not
dependent on renal function and their activity is
unaffected by CRF.
The hepatic metabolism of both enflurane and
sevoflurane will produce nephrotoxic fluoride ions and
their use should be discouraged for prolonged durations
Atracurium and cisatracurium are obvious choices for
muscle relaxation.
The excretion of anticholinesterases and anticholinergic
agents will be prolonged as they are highly ionised and
water soluble.
Avoid NSAIDS
52. POST TRANSPLANT STATE
A chronic kidney disease - continued organ
dysfunction
Post transplant surgery frequency is ~ 41%
Surgery unrelated to transplant ~ 6%
Incidence and urgency of surgery does not vary
with the source of donor kidney
Mortality related to the degree of
immunosuppression and not additional operation.
53. Problems In Post Renal transplant
1. Persistent cardiovascular disease
2. Bone disorders
3. Electrolyte and acid base
imbalance
4. Post transplant Diabetes Mellitus
5. Malignancy
6. Infection
54. 1. CARDIOVASCULAR DISEASE
Most common cause of mortality in those
with functional grafts – 30-40%
Increased incidence of : coronary heart
disease, CHF, ventricular hypertrophy,
hypertension, cerebrovascular disease,
peripheral vascular disease.
59. 2. BONE DISORDERS
HYPERPARATHYROIDISM
Very common in 1st post transplant
year
Risk factors –
Degree of pre- transplant disease
Duration of dialysis
Contributing factors-
Deficiency of vitamin D
Poor allograft function
60. BONE DISORDERS –
HYPERPARATHYROIDISM contd.
Symptoms – mostly asymptomatic
Dx – increased plasma Ca
decreased plasma phosphate
Rx – vitamin D analogs (stopped if S
Ca.>11mg/dl )
- phosphate supplements
61. BONE DISORDERS - HYPERPARATHYROIDISM
contd.
Surgery – indications –
1) severe symptomatic hypercalemia in early post
transplant period
2) persistent moderately severe hypercalcemia for
> one year post transplantation
Surgery done – subtotal parathyroidectomy
62. 2. BONE DISORDERS
GOUT
Cyclosporine – most
important cause
Impairs renal uric acid
clearance
Rx –
Colchicine
High dose steroids
Synthesis inhibitor i.e.
Allopurinol ( dec. dose of
azathioprine)
NSAIDS – Avoid
64. 2. BONE DISORDERS
OSTEOPOROSIS
Common bone disorder- parallel reduction in bone
mineral and bone matrix→ Decreased bone mass
Maximum bone loss – first 6 month
65. BONE DISORDERS –
OSTEOPOROSIS contd.
Causes
Steroids
Ongoing hyperparathyroidism
Vit D def /resistance
Phosphate depletion
Rx
Weight bearing exercise
Steroid minimization
Elemental calcium and calcitriol
Clinical implication – Increased risk of fracture
67. ELECTROLYTE IMBALANCE contd.
HYPOPHOSPHATEMIA
Due to excess urinary excretion
residual hyperparathyroidism
Glucocorticoids
low Vit D state
Implication – Profound respiratory muscle weakness
68. ELECTROLYTE IMBALANCE contd.
HYPERCALCEMIA
Causes –
Persistent Hyperparathyroidism
Co- administration of calcium and vit D
Implication – shortened Q-T interval and
arrhythmias
69. ELECTROLYTE IMBALANCE contd.
HYPOMAGNESEMIA
Cause - CNI induced
Asymptomatic
Rx – magnesium supplements if plasma Mg levels <
1.5mg/dl
Clinical implication - ↑ risk of perioperative
arrhythmias, impaired respiratory muscle power
70. ACID BASE IMBALANCE
METABOLIC ACIDOSIS
Causes
Distal (hyperchloremic) renal tubular acidosis -
occurs due to:
CNI
Rejection
Residual hyperparathyroidism
Clinical Implication - intraoperative electrolyte
imbalance
prolonged NM blockade
interference with drug PK
71. 4. POST TRANSPLANT DIABETES
MELLITUS
New onset DM –
Common
Increased CV risk
Risk factors –
Older age
Obesity
Positive hepatitis C
antibody status
Family history
Deceased donor
allograft
Steroids
CNI
Episodes of acute
rejection
72. POST TRANSPLANT DM (contd)
Rx
Steroids minimized
Tacrolimus avoided
Oral hypoglycemic drugs and Insulin
Metformin- most effective
73. 5.MALIGNANCY
Causes of ↑ cancer incidence –
Immunosuppressants → inhibit normal tumor
↓ surveillance
mechanisms
uncontrolled proliferation
of oncogenic viruses
Factors related to primary renal disease ( analgesic
abuse, HBV , HCV, certain herbal preparations)
Renal cystic disease
74. MALIGNANCY contd.
Treatment
↓ the dose of immunosuppression
Sirolimus – increasing evidence of
antineoplastic effects
Post Transplant Lymphoproliferative Disorder
(PTLD)
1-2% incidence
Feared complication
Cause- Infection and transformation of B cell by
EBV
75. INFECTIONS (contd.)
0-1 MONTH - ~ to those seen in non transplant
patients after surgery.
UTI
lung infections
related to vascular catheters
Bacterial> fungal
77. INFECTIONS (contd.)
> 6 MONTHS – risk of infection decreases
can be divided into 2 groups –
1) Good graft function, no need of late
supplemental immunosuppression – infection
risk similar to general population
2) Poor graft function, received large cumulative
doses of immunosuppression – remain at risk of
oppurtunistic infection
-need long term SMX- TMP prophylaxis
78. INFECTIONS (contd.)
Clinical implication –
Minimizing infection should be the goal
Require meticulous surgical technique
Antiviral prophylaxis
Avoidance of excess immunosuppression
79. Common surgical indications
First 48 hrs of transplant:
Rexploration for bleeding/reduced urine/thrombosis
of graft
Late presentations:
Graft failure: Redo surgery
Uncontrolled hypertension-- Nephrectomy
Lymphoceles, Wound infections
Joint replacements (renal osteodystrophy,
steroid)
Cesarean Sections
GI bleed, CABG, dental (gum hyperplasia)
80. Anesthetic challenges &
preoperative assessment
Avoidance of infection: Maintain sterility
Signs of intra-abdominal sepsis..often absent
fever, leukocytosis, peritonitis signs absent
Assess/Preserve graft function:
previous episodes of rejection
BU, S.Cr, SE (Na,K,Ca,Mg)
Avoid nephrotoxic drugs
86. Monitoring
Perioperative monitoring: risk/benefit
type of surgery
anesthesia planned
equipment available
CVP monitoring:
Transplanted kidneys sensitive to hypovolemia
Diuretic use: adequate intravascular volume
urine output
87. Technique
General (balanced & TIVA) as well as regional
successfully used
General anaesthesia
Nasal intubation better avoided
Use of LMA acceptable
Ketamine: cautious in HTN/CAD
89. Muscle relaxants
Atracurium, Cisatracurium usually preffered
Vecuronium should be prevented –reno
vasoconstriction
Delayed gastric emptying/RSI:
Sch: K<5.5 meq/L
Rocuronium, miva
90. Analgesia
Avoid NSAIDS:
GI Hmge, nephrotoxicity
Augment Cyclosporine A nephrotoxicity
Opiate analgesics often used
Meperidine,M3G and M6G: prolonged sedation
Remifentanyl@ 0.1-0.5 mics/kg/min:
short acting
Non specific tissue and plasma esterases
92. POST OP CARE
PAIN –
Opioid based pain relief
Morphine , pethidine – avoid if RFT deranged
Paracetamol - in paediatric patients
NSAIDS to be avoided
Epidural analgesia
93. POST OP CARE
Cardiovascular collapses have occured upto 2
days post op.
All monitoring should be continued till 2nd post op
day.
In patients with CV disease :
Perioperative beta blockers – can be considered
Maintain normothermia
Haematocrit > 30%
Adequate analgesia
Editor's Notes
Sirolimus – so used in recipients who develops cancer